Hospitalisations and emergency department visits due to drug–drug interactions: a literature review

Becker, Matthijs L.; Kallewaard, Marjon; Caspers, Peter; Visser, Loes E.; Leufkens, Hubert G. M.; Stricker, Bruno H. Ch.

doi:10.1002/pds.1351

Cited by 263 publications

(237 citation statements)

References 30 publications

Supporting

Mentioning

217

Contrasting

Unclassified

Order By: Relevance

“…The presence within the kidney of this common pathway for the secretion of OCs sets the stage for unwanted drug-drug interactions (DDIs) (Lepist and Ray, 2012). The clinical cost of DDIs is substantial and responsible for approximately 1% of hospital admissions (almost 5% in elderly populations) [Becker et al, 2007; U.S. Food and Drug Administration, Preventable adverse drug reactions: A focus on drug interactions (http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ DevelopmentResources/DrugInteractionsLabeling/ucm110632. htm)]; therefore, the ability to predict potential DDIs could lead to decreased morbidity and increased monetary savings.…”

Section: Introductionmentioning

confidence: 99%

Lack of Influence of Substrate on Ligand Interaction with the Human Multidrug and Toxin Extruder, MATE1

et al. 2016

View full text Add to dashboard Cite

Multidrug and toxin extruder (MATE) 1 plays a central role in mediating renal secretion of organic cations, a structurally diverse collection of compounds that includes ∼40% of prescribed drugs. Because inhibition of transport activity of other multidrug transporters, including the organic cation transporter (OCT) 2, is influenced by the structure of the transported substrate, the present study screened over 400 drugs as inhibitors of the MATE1-mediated transport of four structurally distinct organic cation substrates: the commonly used drugs: 1) metformin and 2) cimetidine; and two prototypic cationic substrates, 3) 1-methyl-4-phenylpyridinium (MPP), and 4) the novel fluorescent probe, N,N,N-trimethyl-2-[methyl(7-Transport was measured in Chinese hamster ovary cells that stably expressed the human ortholog of MATE1. Comparison of the resulting inhibition profiles revealed no systematic influence of substrate structure on inhibitory efficacy. Similarly, IC 50 values for 26 structurally diverse compounds revealed no significant influence of substrate structure on the kinetic interaction of inhibitor with MATE1. The IC 50 data were used to generate three-dimensional quantitative pharmacophores that identified hydrophobic regions, H-bond acceptor sites, and an ionizable (cationic) feature as key determinants for ligand binding to MATE1. In summary, in contrast to the behavior observed with some other multidrug transporters, including OCT2, the results suggest that substrate identity exerts comparatively little influence on ligand interaction with MATE1.

show abstract

Section: Introductionmentioning

confidence: 99%

Lack of Influence of Substrate on Ligand Interaction with the Human Multidrug and Toxin Extruder, MATE1

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In 2007, a meta-analysis of 23 clinical studies from around the world revealed that drug-drug interactions (DDIs) cause approximately 0.054% of emergency room visits, 0.57% of hospital admissions, and 0.12% of rehospitalizations [7]. There are 136.1 million emergency room visits [8] Aim: To detect potential drug-drug interactions among medications received by hypertensive patients.…”

Section: Introductionmentioning

confidence: 99%

Potential Drug - Drug Interactions among Medications Prescribed to Hypertensive Patients

Kothari

Ganguly

2014

JCDR

View full text Add to dashboard Cite

“…For instance, drug interactions, especially with medications having a narrow therapeutic range, may have serious adverse outcomes. A literature search in Medline and Embase database from 1990 to 2006 illustrated that drug-drug interactions (DDIs) were detained accountable for 0.054 % of the emergency department (ED) visits, 0.57 % of the hospital admissions, and 0.12 % of the re-hospitalizations (Becker et al, 2007). It is conceivable that medication connection can be helpful or hindering.…”

Section: Introductionmentioning

confidence: 99%

In vitro, in vivo and in silico drugdrug interaction study between Vildagliptin and Bisoprolol fumarate

et al. 2018

View full text Add to dashboard Cite

Aim of the present study is to evaluate the in vitro, in vivo and in silico drug-drug interaction between Vildagliptin and Bisoprolol fumarate. Interaction between Vildagliptin and Bisoprolol fumarate has been studied in a system of water at a fixed 37 0 C at pH 1.0, 3.0 and 6.8 by using spectral observation, Job's method of continuous variation, Ardon's method. In silico complexation was measured by NMR prediction and DDI-CPI analysis. From spectrophotometric study, Vildagliptin and Bisoprolol fumarate give different spectra when Vildagliptin mixed with Bisoprolol fumarate in 1:1 mixture, intensity of spectra of Vildagliptin transform surprisingly due to interaction. The jobs plot was attained by plotting absorbance difference (D) against the mole fraction of the each drug at pH 1, 3, and 6.8. Vildagliptin moderate for 1:1 mixture with Bisoprolol fumarate and slightly lower spectra indicate the formation of 1:1 mixture of Vildagliptin with Bisoprolol fumarate. The value of stability constant for the drug-drug system at pH 1.0, 3.0 and 6.8 are 1.875 0.7778 and 1.2000 respectively. From the IR report it also proved that Vildagliptin and Bisoprolol fumarate produced interaction. In this OGTT test at 1:1, 1:2 and 2:1 complex blood glucose level decrease compared to Vildagliptin. Because when drug-drug interaction happened, then drug cannot exhibit its main activity. That's why in this test complex showed different activity. In in silico methods, results showed that the drugs interact with each other. So, a careful concern is desired during simultaneous administration of Vildagliptin with Bisoprolol fumarate.

show abstract

Hospitalisations and emergency department visits due to drug–drug interactions: a literature review

Cited by 263 publications

References 30 publications

Lack of Influence of Substrate on Ligand Interaction with the Human Multidrug and Toxin Extruder, MATE1

Lack of Influence of Substrate on Ligand Interaction with the Human Multidrug and Toxin Extruder, MATE1

Potential Drug - Drug Interactions among Medications Prescribed to Hypertensive Patients

In vitro, in vivo and in silico drugdrug interaction study between Vildagliptin and Bisoprolol fumarate

Contact Info

Product

Resources

About